January 30, 2022 Journal article Open Access

Ahan Gadkari; Sofia Dash

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://zenodo.org/record/5804101</identifier>
  <creators>
    <creator>
      <creatorName>Ahan Gadkari</creatorName>
      <affiliation>4th Year BA. LLB Candidate, O.P. Jindal Global  University, Jindal Global Law School, Sonipat, India.</affiliation>
    </creator>
    <creator>
      <creatorName>Sofia Dash</creatorName>
      <affiliation>1st Year BA. LLB Candidate, O.P. Jindal Global University,  Jindal Global Law School, Sonipat, India.</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Not Tripping over TRIPS: An Analysis of  Necessity and Legality of the COVID-19 TRIPS  Waiver Proposal</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2022</publicationYear>
  <subjects>
    <subject>Intellectual Property Rights, COVID-19 Vaccines, TRIPS Agreement, WTO</subject>
    <subject subjectScheme="issn">2277-3878</subject>
    <subject subjectScheme="handle">100.1/ijrte.E66750110522</subject>
  </subjects>
  <contributors>
    <contributor contributorType="Sponsor">
      <contributorName>Blue Eyes Intelligence Engineering  and Sciences Publication (BEIESP)</contributorName>
      <affiliation>Publisher</affiliation>
    </contributor>
  </contributors>
  <dates>
    <date dateType="Issued">2022-01-30</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/5804101</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="ISSN" relationType="IsCitedBy" resourceTypeGeneral="JournalArticle">2277-3878</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.35940/ijrte.E6675.011052</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;The availability of vaccinations against COVID-19 provides hope for containing the epidemic, which has already claimed over 2.84 million lives. However, inoculating millions of individuals worldwide would need large vaccine manufacturing followed by fair distribution. A barrier to vaccine development and dissemination is the developers&amp;#39; intellectual property rights. India and South Africa have jointly sought to the World Trade Organization that certain TRIPS rules of COVID-19 vaccines, medicines, and treatments be waived. This piece argues for such a waiver, highlighting the unique circumstances that exist. It believes that TRIPS&amp;#39;s flexibilities are inadequate to cope with the present epidemic, particularly for nations without pharmaceutical manufacturing competence.&lt;/p&gt;</description>
  </descriptions>
</resource>